EUVIMEDAtrasti EUVIMED
Crossref

Engineered Biomimetic Nanovesicles Synergistically Remodel Folate-Nucleotide and γ-Aminobutyric Acid Metabolism to Overcome Sunitinib-Resistant Renal Cell Carcinoma

Minchao Lv iD, Bin Liu, Yi Duan, Jiangtao Lin, Li Dai, Yuanyuan Li, Jian Yu, Jinghan Liao, Jiali Zhang iD, Yourong Duan iD

ACS Nano · 2024-10-08 · 18 (40) · 27487-27502

DOI: 10.1021/acsnano.4c08055 ↗

At a glance

Journal article in ACS Nano, published online on 2024-09-27. Written by Minchao Lv and 9 co-authors. Institution: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 22…. Major MEDLINE topics: Carcinoma, Renal Cell, Drug Resistance, Neoplasm, Kidney Neoplasms, Folic Acid. Cited 17 times so far (Crossref); 72 references. Funded by: Natural Science Foundation of Shanghai Municipality, Innovative Research Team of High-level Local University in Shanghai, National Natural Science Foundation of China.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Reprogramming of cellular metabolism in tumors promoted the epithelial-mesenchymal transition (EMT) process and established immune-suppressive tumor microenvironments (iTME), leading to drug resistance and tumor progression. Therefore, remodeling the cellular metabolism of tumor cells was a promising strategy to overcome drug-resistant tumors. Herein, CD276 and MTHFD2 were identified as a specific marker and a therapeutic target, respectively, for targeting sunitinib-resistant clear cell renal cell carcinoma (ccRCC) and its cancer stem cell (CSC) population. The blockade of MTHFD2 was confirmed to overcome drug resistance via remodeling of folate-nucleotide metabolism. Moreover, the manganese dioxide nanoparticle was proven here by a high-throughput metabolome to be capable of remodeling γ-aminobutyric acid (GABA) metabolism in tumor cells to reconstruct the iTME. Based on these findings, engineered CD276-CD133 dual-targeting biomimetic nanovesicle EMφ-siMTHFD2-MnO2@Suni was designed to overcome drug resistance and terminate tumor progression of ccRCC. Using ccRCC-bearing immune-humanized NPG model mice, EMφ-siMTHFD2-MnO2@Suni was observed to remodel folate-nucleotide and GABA metabolism to deactivate the EMT process and reconstruct the iTME thereby overcoming the drug resistance. In the incomplete-tumor-resection recurrence model and metastasis model, EMφ-siMTHFD2-MnO2@Suni reduced recurrence and metastasis in vivo. This work thus provided an innovative approach that held great potential in the treatment of drug-resistant ccRCC by remodeling cellular metabolism.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Renal CellDrug Resistance, NeoplasmKidney NeoplasmsFolic AcidSunitinibgamma-Aminobutyric AcidManganese CompoundsHumansAnimalsMiceNanoparticlesNucleotidesAntineoplastic AgentsBiomimetic MaterialsCell Line, TumorTumor MicroenvironmentCell ProliferationEpithelial-Mesenchymal TransitionAminohydrolasesMethylenetetrahydrofolate Dehydrogenase (NADP)OxidesMultifunctional Enzymes

Author keywords

cancer stem cellscellular metabolic remodelingdrug-resistant clear cell renal cell carcinomaengineered biomimetic nanovesiclesimmune-suppressive tumor microenvironment

Substances

Folic AcidSunitinibgamma-Aminobutyric AcidManganese CompoundsNucleotidesAntineoplastic Agentsmanganese dioxideMTHFD2 protein, humanAminohydrolasesMethylenetetrahydrofolate Dehydrogenase (NADP)

Authors and institutions

  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 2200/25 Xietu Rd, Shanghai 200032, China.
  • Department of Otolaryngology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1678 Dongfang Rd, Shanghai 200127, China.

ORCID profiles: Minchao Lv, Jiali Zhang, Yourong Duan

Funding

  • Natural Science Foundation of Shanghai Municipality
  • Innovative Research Team of High-level Local University in Shanghai
  • National Natural Science Foundation of China

Cite

APA

Lv, M., Liu, B., Duan, Y., Lin, J., Dai, L., Li, Y., Yu, J., Liao, J., Zhang, J., & Duan, Y. (2024). Engineered Biomimetic Nanovesicles Synergistically Remodel Folate-Nucleotide and γ-Aminobutyric Acid Metabolism to Overcome Sunitinib-Resistant Renal Cell Carcinoma. ACS Nano, 18(40), 27487-27502. https://doi.org/10.1021/acsnano.4c08055

Vancouver

Lv M, Liu B, Duan Y, Lin J, Dai L, Li Y, et al. Engineered Biomimetic Nanovesicles Synergistically Remodel Folate-Nucleotide and γ-Aminobutyric Acid Metabolism to Overcome Sunitinib-Resistant Renal Cell Carcinoma. ACS Nano. 2024;18(40):27487-27502. doi:10.1021/acsnano.4c08055

BibTeX
@article{Lv2024,
  author = {Lv, Minchao and Liu, Bin and Duan, Yi and Lin, Jiangtao and Dai, Li and Li, Yuanyuan and Yu, Jian and Liao, Jinghan and Zhang, Jiali and Duan, Yourong},
  title = {Engineered Biomimetic Nanovesicles Synergistically Remodel Folate-Nucleotide and γ-Aminobutyric Acid Metabolism to Overcome Sunitinib-Resistant Renal Cell Carcinoma},
  journal = {ACS Nano},
  year = {2024},
  volume = {18},
  number = {40},
  pages = {27487--27502},
  doi = {10.1021/acsnano.4c08055}
}
Start for free →